



## Ubiquitin: What It Is and Its Role in Targeted Cancer Therapy

Guest Editor:

**Prof. Dr. Jerry Vriend**

Department of Human Anatomy  
and Cell Science, Max Rady  
College of Medicine, Rady Faculty  
of Health Sciences, University of  
Manitoba, Winnipeg, MB R3E 0J9,  
Canada

Deadline for manuscript  
submissions:  
**closed (31 August 2022)**

### Message from the Guest Editor

The ubiquitin proteasome system regulates the activity of many proteins in cells. Ubiquitin is added to proteins by a three step process sequentially involving ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3).

In this Special Issue, we are interested in original research and/or reviews on the role of the ubiquitin proteasome system in transformation, invasiveness, proliferation, and maintenance of various cancer cells. From a practical point of view, ubiquitin ligases and their adaptors provide a large number of therapeutic targets, most of which remain unidentified. The challenge is to identify them and to engineer small specific molecular inhibitors which alone, or in conjunction with chemotherapeutic agents, improve the outcome of cancers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)